New antibody drug could open door to kidney transplants for Hard-to-Match patients

NCT ID NCT05092347

Ongoing Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called vonsetamig in 43 people with chronic kidney disease who are on dialysis and have very high levels of anti-HLA antibodies, making it nearly impossible to find a matching kidney donor. The drug aims to safely lower these antibodies so that a kidney transplant becomes possible. Researchers are also monitoring side effects and how the drug works in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (CKD)

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Comprehensive Transplant Center

Chicago, Illinois, 60611, United States
Connie Frank Transplant Center at UCSF

San Francisco, California, 94143, United States
John Hopkins Hospital

Baltimore, Maryland, 21224, United States
Medstar Georgetown Transplant Institute - 2-PHC

Washington D.C., District of Columbia, 20007, United States
New York University Langone Health

New York, New York, 10016, United States
Penn Transplant Institute

Philadelphia, Pennsylvania, 19104, United States
University of California Irvine

Orange, California, 92868, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States
Yale University of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.